EU agency for medicines evaluation and supervision
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.